Payment overview · 2025
General Payments
$212.09
10 reported records · 6 companies
Healthcare provider profile · identity verified
Laura Johnson, MD
Allopathic & Osteopathic Physicians|Family Medicine · NOBLESVILLE, IN · NPI 1952414666
Verified facts
What the public records show
CMS Open Payments records show Laura Johnson, MD received $212.09 in general payments during 2025 across 10 reported records.
Novo Nordisk Inc accounted for 29.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Mounjaro, Ozempic, Shingrix, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $62.64 | 29.5% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $51.52 | 24.3% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $31.64 | 14.9% | 2 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $24.53 | 11.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $21.17 | 10.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $20.59 | 9.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $212.09 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $51.52 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $48.08 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $48.08 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $31.64 | 2 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $24.53 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $21.17 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $21.17 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $20.59 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $20.59 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.30 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $15.34 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.34 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.56 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 47 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 52 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 73 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 44 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
59 | 25 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
47 | 47 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
44 | 41 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
84 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
52 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
73 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 727 | 258 |
| Levothyroxine Sodium | Levothyroxine Sodium | 458 | 134 |
| Amlodipine Besylate | Amlodipine Besylate | 358 | 152 |
| Losartan Potassium | Losartan Potassium | 277 | 98 |
| Lisinopril | Lisinopril | 243 | 89 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 238 | 83 |
| Omeprazole | Omeprazole | 220 | 82 |
| Pantoprazole Sodium | Pantoprazole Sodium | 198 | 70 |
| Gabapentin | Gabapentin | 196 | 66 |
| Metoprolol Succinate | Metoprolol Succinate | 190 | 73 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 169 | 49 |
| Trazodone Hcl | Trazodone Hcl | 153 | 59 |
| Metformin Hcl | Metformin Hcl | 149 | 55 |
| Furosemide | Furosemide | 144 | 51 |
| Alprazolam | Alprazolam | 139 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 128 | 49 |
| Escitalopram Oxalate | Escitalopram Oxalate | 126 | 51 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 126 | 45 |
| Simvastatin | Simvastatin | 125 | 41 |
| Tramadol Hcl | Tramadol Hcl | 120 | 45 |
| Alendronate Sodium | Alendronate Sodium | 116 | 42 |
| Sertraline Hcl | Sertraline Hcl | 114 | 45 |
| Zolpidem Tartrate | Zolpidem Tartrate | 109 | 34 |
| Glipizide Er | Glipizide | 106 | 39 |
| Pravastatin Sodium | Pravastatin Sodium | 105 | 43 |
| Meloxicam | Meloxicam | 104 | 38 |
| Metformin Hcl Er | Metformin Hcl | 103 | 46 |
| Metoprolol Tartrate | Metoprolol Tartrate | 103 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 95 | 41 |
| Atenolol | Atenolol | 89 | 30 |
| Famotidine | Famotidine | 86 | 33 |
| Fluoxetine Hcl | Fluoxetine Hcl | 84 | 24 |
| Jardiance | Empagliflozin | 84 | 26 |
| Diclofenac Sodium | Diclofenac Sodium | 83 | 23 |
| Bupropion Xl | Bupropion Hcl | 82 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 77 | 31 |
| Montelukast Sodium | Montelukast Sodium | 76 | 26 |
| Carvedilol | Carvedilol | 75 | 23 |
| Ezetimibe | Ezetimibe | 74 | 27 |
| Clonazepam | Clonazepam | 73 | 25 |
| Ozempic | Semaglutide | 73 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 68 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 65 | 26 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 65 | 14 |
| Potassium Chloride | Potassium Chloride | 64 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 61 | 26 |
| Synthroid | Levothyroxine Sodium | 59 | 25 |
| Allopurinol | Allopurinol | 58 | 25 |
| Eliquis | Apixaban | 58 | 22 |
| Celecoxib | Celecoxib | 57 | 19 |
| Prednisone | Prednisone | 56 | 40 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 55 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 54 | 19 |
| Lorazepam | Lorazepam | 54 | 13 |
| Mirtazapine | Mirtazapine | 52 | 17 |
| Mounjaro | Tirzepatide | 52 | 15 |
| Spironolactone | Spironolactone | 51 | 19 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 47 | 47 |
| Tizanidine Hcl | Tizanidine Hcl | 46 | 19 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 45 | 45 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 44 | 41 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 43 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 43 | 15 |
| Sumatriptan Succinate | Sumatriptan Succinate | 42 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 41 | 15 |
| Valsartan | Valsartan | 41 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 40 | suppressed |
| Cephalexin | Cephalexin | 39 | 28 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 39 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 36 | 29 |
| Estradiol | Estradiol | 35 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 35 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 33 | 12 |
| Enalapril Maleate | Enalapril Maleate | 32 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 32 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 32 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 31 | 12 |
| Finasteride | Finasteride | 31 | 13 |
| Buspirone Hcl | Buspirone Hcl | 30 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 30 | suppressed |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Amoxicillin | Amoxicillin | 26 | 23 |
| Irbesartan | Irbesartan | 26 | 12 |
| Topiramate | Topiramate | 26 | suppressed |
| Nystatin | Nystatin | 25 | 14 |
| Glipizide | Glipizide | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 22 | 12 |
| Diazepam | Diazepam | 22 | suppressed |
| Glimepiride | Glimepiride | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Pregabalin | Pregabalin | 21 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Ketoconazole | Ketoconazole | 20 | 11 |
| Risperidone | Risperidone | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 12 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Victoza 2-Pak | Liraglutide | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 12 |
| Fluconazole | Fluconazole | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $212.09 · 10 records | Novo Nordisk Inc | AREXVY, BEXSERO, Kerendia, MOUNJARO, Ozempic, QULIPTA, Rybelsus, SHINGRIX, SPRAVATO, TRELEGY ELLIPTA, UBRELVY, Wegovy, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error